Life Science

A weak inhibitor of PKC demonstrating an IC₅₀ value &gt100 &microM blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC₅₀ value of 8 &microM.

A selective PKC inhibitor (IC₅₀ = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC exhibits PKC isozyme specificity with preference for PKC&alpha over PKC&betaI, PKC&betaII, PKC&gamma, or PKC&epsilon

A selective PKC inhibitor (IC₅₀ = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC exhibits PKC isozyme specificity with preference for PKC&alpha over PKC&betaI, PKC&betaII, PKC&gamma, or PKC&epsilon

A selective PKC inhibitor (IC₅₀ = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC exhibits PKC isozyme specificity with preference for PKC&alpha over PKC&betaI, PKC&betaII, PKC&gamma, or PKC&epsilon

A cell-permeable, reversible, ATP-competitive PKC inhibitor (IC₅₀ = 15 nM, rat brain PKC) inhibits PKC&alpha, &betaI, &betaII, &gamma, and &epsilon with IC₅₀ values of 8, 8, 14, 13, and 39 nM, respectively also inhibits

A cell-permeable, reversible, ATP-competitive PKC inhibitor (IC₅₀ = 15 nM, rat brain PKC) inhibits PKC&alpha, &betaI, &betaII, &gamma, and &epsilon with IC₅₀ values of 8, 8, 14, 13, and 39 nM, respectively also inhibits

A selective, cell-permeable PKC inhibitor that displays 10-fold greater selectivity for PKC&alpha (IC50 = 9 nM) and 4-fold greater selectivity for PKC&betaI (IC50 = 28 nM) over Ca2+-independent PKC&epsilon (IC50 = 108 nM) prevents T-cell

A selective, cell-permeable PKC inhibitor that displays 10-fold greater selectivity for PKC&alpha (IC50 = 9 nM) and 4-fold greater selectivity for PKC&betaI (IC50 = 28 nM) over Ca2+-independent PKC&epsilon (IC50 = 108 nM) prevents T-cell

A potent RSK2 inhibitor (IC₅₀ = 1.1 nM) that also demonstrates off-target binding at multiple adrenergic receptor subtypes that are important for vascular tone and cardiac function (IC₅₀s = 0.

A potent RSK2 inhibitor (IC₅₀ = 1.1 nM) that also demonstrates off-target binding at multiple adrenergic receptor subtypes that are important for vascular tone and cardiac function (IC₅₀s = 0.

A potent RSK2 inhibitor (IC₅₀ = 1.1 nM) that also demonstrates off-target binding at multiple adrenergic receptor subtypes that are important for vascular tone and cardiac function (IC₅₀s = 0.

A selective inhibitor of G9a histone methyltransferase (IC₅₀ = 1.7 &muM) less effectively inhibits G9a-like protein (GLP IC₅₀ = 38 &muM) and has no effect on other known histone methyltransferases.